4-bromo-N1-phenylbenzene-1,2-diamine | 68765-53-7

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 4-bromo-N1-phenylbenzene-1,2-diamine
• 英文别名: 4-bromo-1-N-phenylbenzene-1,2-diamine
• CAS: 68765-53-7
• 化学式: C₁₂H₁₁BrN₂
• 分子量: 263.137
• InChiKey: NBTKUAXTHMSWFA-UHFFFAOYSA-N

物化性质

• 熔点：
  79-80 °C
• 沸点：
  370.4±32.0 °C(Predicted)
• 密度：
  1.512±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  3.5
• 重原子数：
  15
• 可旋转键数：
  2
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  38
• 氢给体数：
  2
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  4-bromo-N1-phenylbenzene-1,2-diamine 在 (1,1'-bis(diphenylphosphino)ferrocene)palladium(II) dichloride 、 potassium acetate 、 联硼酸频那醇酯 作用下， 以 N,N-二甲基甲酰胺 为溶剂， 生成
  参考文献：
  名称：

  Design and synthesis of 1,5-diarylbenzimidazoles as inhibitors of the VEGF-receptor KDR

  摘要：

  1, 5-Diarylbenzimidazoles have been identified as potent inhibitors of KDR kinase activity. The series was developed with a goal of finding compounds with optimal drug-like properties. This communication describes structural modifications in the series that enhance solubility, lower protein binding, and provide compounds with excellent potency and pharmacokinetic profiles. (C) 2003 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/s0960-894x(03)00485-2
• 作为产物：
  描述：

  2,5-二溴硝基苯 在 sodium sulfide 、 sodium acetate 、 sulfur 作用下， 以 水 为溶剂， 反应 13.0h， 生成 4-bromo-N1-phenylbenzene-1,2-diamine
  参考文献：
  名称：

  带有 BODIPY 取代的 N-杂环卡宾 (NHC) 配体的中性铱 (iii) 配合物：合成、光物理学、体外治疗诊断光动力疗法和抗菌活性†

  摘要：

  报道了一系列新型中性杂配环金属化铱 ( III ) 配合物的合成、光物理和光生物学活性，这些配合物包含硼二吡咯亚甲基 (BODIPY) 取代的 N-杂环卡宾 (NHC) 配体 ( Ir1–Ir5 )。NHC配体上BODIPY的取代位置（苯环的C4（Ir1-Ir3）或苯并咪唑单元的C5（Ir4和Ir5））及其连接体类型（单键或三键）对光物理性能的影响性质进行了研究。Ir1–Ir5在 530–543 nm处表现出 BODIPY 局部强烈的1 IL（配体内跃迁）/ 1 MLCT（金属到配体电荷转移）吸收，并在582 nm 处表现出1,3 IL/ 1,3 CT（电荷转移）发射。 610 纳米。纳秒瞬态吸收结果表明，这些配合物的最低三重激发态是BODIPY局域的3 π,π*态。与配合物Ir1和Ir3中相应的吸收和发射带相比，配合物Ir4和Ir5表现出蓝移的1IL吸收和1,3IL / 1,3CT发射带

  DOI：

  10.1039/c9pp00142e

文献信息

• NITROGEN-CONTAINING HETEROCYCLIC DERIVATIVE AND ORGANIC ELECTROLUMINESCENT DEVICE USING THE SAME
  申请人：Idemitsu Kosan Co., Ltd.

  公开号：EP2236501A1

  公开（公告）日：2010-10-06

  A novel nitrogen-containing heterocyclic derivative having a specific structure. An organic electroluminescence device comprises an organic thin-film layer which is disposed between a cathode and an anode and comprises one or more layers having a light emitting layer. At least one layer of the organic thin-film layer comprises the nitrogen-containing heterocyclic derivative. The organic electroluminescence device exhibits a high luminance and a high luminous efficiency even at a low driving voltage.

  一种具有特定结构的新型含氮杂环衍生物。一种有机电致发光器件包括一个有机薄膜层，该有机薄膜层位于阴极和阳极之间，并包括一个或多个具有发光层的层。有机薄膜层的至少一层包括含氮杂环衍生物。该有机电致发光器件在低驱动电压下表现出高亮度和高发光效率。
• Combined treatment with an EGFR kinase inhibitor and an agent that sensitizes tumor cells to the effects of EGFR kinase inhibitors
  申请人：Buck A. Elizabeth

  公开号：US20070280928A1

  公开（公告）日：2007-12-06

  The present invention provides a method for treating NSCL, pancreatic, colon or breast cancer tumors or tumor metastases in a patient, comprising administering to the patient simultaneously or sequentially a therapeutically effective amount of a combination of an EGFR kinase inhibitor and an agent that sensitizes tumor cells to the effects of EGFR kinase inhibitors, wherein the agent is an mTOR inhibitor, with or without additional agents or treatments, such as other anti-cancer drugs or radiation therapy. The present invention also provides a method for treating tumors or tumor metastases in a patient, comprising administering to said patient simultaneously or sequentially a therapeutically effective amount of a combination of an EGFR kinase inhibitor and an agent that sensitizes tumor cells to the effects of EGFR kinase inhibitors, wherein said agent is an mTOR inhibitor that binds to and directly inhibits both mTORC1 and mTORC2 kinases. The present invention also provides a pharmaceutical composition comprising an EGFR kinase inhibitor and an mTOR inhibitor that binds to and directly inhibits both mTORC1 and mTORC2 kinases, in a pharmaceutically acceptable carrier. A preferred example of an EGFR kinase inhibitor that can be used in practicing the methods of this invention is the compound erlotinib HCl (also known as TARCEVA®).

  本发明提供了一种治疗患者体内NSCL、胰腺、结肠或乳腺癌肿瘤或肿瘤转移的方法，包括向患者同时或顺序给予治疗有效量的EGFR激酶抑制剂和一种使肿瘤细胞对EGFR激酶抑制剂产生敏感性的药物的组合，其中该药物是mTOR抑制剂，可以附加其他药物或治疗，如其他抗癌药物或放射治疗。本发明还提供了一种治疗患者体内肿瘤或肿瘤转移的方法，包括向患者同时或顺序给予治疗有效量的EGFR激酶抑制剂和一种使肿瘤细胞对EGFR激酶抑制剂产生敏感性的药物的组合，其中该药物是一种能够结合并直接抑制mTORC1和mTORC2激酶的mTOR抑制剂。本发明还提供了一种制药组合物，包括一种能够结合并直接抑制mTORC1和mTORC2激酶的EGFR激酶抑制剂和mTOR抑制剂，以及一种药用载体。本发明中可用于实施该方法的EGFR激酶抑制剂的首选示例是化合物厄洛替尼盐酸盐（也称为TARCEVA®）。
• Fused bicyclic mTOR inhibitors
  申请人：Chen Xin

  公开号：US20070112005A1

  公开（公告）日：2007-05-17

  Compounds represented by Formula (I) or a pharmaceutically acceptable salt thereof, are inhibitors of mTOR and useful in the treatment of cancer.

  由化学式(I)代表的化合物或其药用可接受的盐，是mTOR的抑制剂，可用于癌症的治疗。
• ORGANOMETALLIC COMPOUND AND ORGANIC LIGHT-EMITTING DEVICE INCLUDING THE SAME
  申请人：SAMSUNG DISPLAY CO., LTD.

  公开号：US20200168816A1

  公开（公告）日：2020-05-28

  An organic light-emitting device and an organometallic compound are provided, the organic light-emitting device including a first electrode; a second electrode; and an organic layer between the first electrode and the second electrode and including an emission layer, wherein the organic light-emitting device further includes an organometallic compound represented by Formula 1: wherein, M, Y 1 to Y 4 , T 1 to T 4 , A 1 to A 5 , X 1 , X 2 , L 1 to L 3 , a1 to a3, R 1 to R 5 and b1 to b5 are the same as defined in the specification.

  提供了一种有机发光器件和一种有机金属化合物，其中该有机发光器件包括第一电极；第二电极；以及位于第一电极和第二电极之间的有机层，包括一个发射层，其中该有机发光器件还包括由Formula 1表示的有机金属化合物：其中，M、Y1至Y4、T1至T4、A1至A5、X1、X2、L1至L3、a1至a3、R1至R5和b1至b5与规范中定义的相同。
• 유기 전계 발광 화합물 및 이를 포함하는 유기 전계 발광 소자
  申请人：Rohm and Haas Electronic Materials Korea Ltd. 롬엔드하스전자재료코리아유한회사(120080396402) Corp. No ▼ 161514-0000453

  公开号：KR20150064500A

  公开（公告）日：2015-06-11

  본 발명은 유기 전계 발광 화합물 및 이를 포함하는 유기 전계 발광 소자에 관한 것이다. 본 발명의 유기 전계 발광 화합물을 이용하면, 구동수명이 매우 우수하고, 구동전압이 낮아 전류효율 및 전력효율이 개선된 유기 전계 발광 소자를 제조할 수 있다.

  本发明涉及有机电致发光化合物及包含该化合物的有机电致发光器件。利用本发明的有机电致发光化合物，可以制造出具有优异驱动寿命、低驱动电压、改善电流效率和功率效率的有机电致发光器件。